Shenzhen Wingor Biotechnology Co., Ltd, a Chinese biotechnology company, has entered into a scientific research cooperation agreement with the Guangzhou Institute of Respiratory Health (GIRH). The partnership aims to collaborate on clinical studies focusing on the use of exosomes derived from mesenchymal stem cells (MSC exos) for the treatment of respiratory diseases.
MSC exos are small membrane vesicles secreted by mesenchymal stem cells (MSCs) that contain complex RNA and proteins. These vesicles possess the regenerative repair capabilities of MSCs, along with several advantages such as low immunogenicity, non-teratogenicity, resistance to low temperatures, and ease of transportation and preservation. Research suggests that the cytokines and microRNAs contained in MSC exos may help regulate inflammatory and fibrotic pathways in the lungs, making this cell-free stem-cell therapy a promising new treatment approach for respiratory diseases.
Wingor Bio, known for its large-scale exosome preparation technology (winExm), drug coupling technology (winLiK), and targeted modification technology (winExt), will contribute its expertise to this collaborative research effort.- Flcube.com
